Lipvas 40 Tablet contains Atorvastatin 40 mg, a potent lipid-lowering agent belonging to the statin class of medications. It is primarily indicated for the treatment of hypercholesterolemia and mixed dyslipidemia, helping to reduce elevated levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides, while modestly increasing high-density lipoprotein cholesterol (HDL-C). Atorvastatin exerts its effect by selectively inhibiting HMG-CoA reductase, a key enzyme involved in hepatic cholesterol biosynthesis, leading to increased clearance of LDL-C from the bloodstream. Lipvas 40 is prescribed to reduce the risk of cardiovascular events such as myocardial infarction, stroke, and the need for revascularization procedures in patients with established coronary artery disease or those at high risk due to multiple risk factors. The medication is administered orally, typically once daily, with or without food, and dosage adjustments should be individualized based on therapeutic response and tolerability. Common adverse effects include headache, myalgia, and gastrointestinal disturbances; however, serious adverse reactions such as myopathy and hepatotoxicity are rare but warrant monitoring. Regular liver function tests and lipid profile assessments are recommended during therapy to ensure safety and efficacy. Lipvas 40 should be used cautiously in patients with hepatic impairment and contraindicated during pregnancy and lactation.